Efficacy and Safety of Lower-Sodium Oxybate in an Open-Label Titration Period of a Phase 3 Clinical Study in Adults with Idiopathic Hypersomnia.
Michael J ThorpyIsabelle ArnulfNancy Foldvary-SchaeferAnne Marie MorseKarel SonkaPatricia ChandlerLuke HickeyAbby ChenJed BlackAmanda SterkelDan ChenRichard K BoganYves DauvilliersPublished in: Nature and science of sleep (2022)
During open-label treatment with LXB, participants showed clinically meaningful improvements in idiopathic hypersomnia symptoms and in quality of life and functional measures. TEAE incidence declined over LXB titration and optimization.